Maxim Group analyst Jason McCarthy maintained a Hold rating on VistaGen Therapeutics (VTGN – Research Report) yesterday. The company’s shares opened today at $0.16.
According to TipRanks, McCarthy is an analyst with an average return of -30.6% and a 21.75% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Oncolytics Biotech, and Lineage Therap.
Currently, the analyst consensus on VistaGen Therapeutics is a Hold with an average price target of $0.25.
See today’s best-performing stocks on TipRanks >>
Based on VistaGen Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $17.48 million. In comparison, last year the company earned a revenue of $357.9 thousand and had a GAAP net loss of $10.54 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
Read More on VTGN:
